Company registration number 07843615 (England and Wales)
SHAH PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
PAGES FOR FILING WITH REGISTRAR
SHAH PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
SHAH PHARMACY LIMITED
BALANCE SHEET
AS AT
30 APRIL 2025
30 April 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
229,166
260,416
Tangible assets
4
39,696
32,234
268,862
292,650
Current assets
Stocks
51,349
50,278
Debtors
5
187,917
137,933
Cash at bank and in hand
130,777
46,933
370,043
235,144
Creditors: amounts falling due within one year
6
(209,035)
(208,814)
Net current assets
161,008
26,330
Total assets less current liabilities
429,870
318,980
Provisions for liabilities
(9,924)
(8,059)
Net assets
419,946
310,921
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
419,846
310,821
Total equity
419,946
310,921
SHAH PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2025
30 April 2025
- 2 -

For the financial year ended 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 30 December 2025 and are signed on its behalf by:
Mr SK Patel
Director
Company registration number 07843615 (England and Wales)
SHAH PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
- 3 -
1
Accounting policies
Company information

Shah Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, HA5 5QA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The company recognises revenue from the following major sources:

 

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

SHAH PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 4 -
1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on reducing balance
Computers
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

SHAH PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102,'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
11
11
SHAH PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2024 and 30 April 2025
625,000
Amortisation and impairment
At 1 May 2024
364,584
Amortisation charged for the year
31,250
At 30 April 2025
395,834
Carrying amount
At 30 April 2025
229,166
At 30 April 2024
260,416
4
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
Cost
At 1 May 2024
51,684
18,222
69,906
Additions
16,077
4,019
20,096
At 30 April 2025
67,761
22,241
90,002
Depreciation and impairment
At 1 May 2024
30,680
6,992
37,672
Depreciation charged in the year
8,822
3,812
12,634
At 30 April 2025
39,502
10,804
50,306
Carrying amount
At 30 April 2025
28,259
11,437
39,696
At 30 April 2024
21,004
11,230
32,234
SHAH PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 7 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
154,965
116,096
Amounts owed by group undertakings
9,153
-
0
Other debtors
23,799
21,837
187,917
137,933
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
100,600
107,569
Amounts owed to group undertakings
-
0
12,559
Taxation and social security
70,643
51,653
Other creditors
37,792
37,033
209,035
208,814
7
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

The company incurred expenses of £12,000 representing the rent and management charges paid to a related company controlled by common directors and shareholders on normal commercial terms.

 

Included in other creditors are loans owed to related companies with common directors and shareholders totalling £2,100. The loans are unsecured, interest free and repayable on demand.

 

8
Parent company

The ultimate parent company is Createmore Healthcare Limited which is incorporated in England and Wales.

2025-04-302024-05-01falsefalsefalse30 December 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr AR DattaniMrs SA DattaniMr SK PatelMr RM Shah078436152024-05-012025-04-30078436152025-04-30078436152024-04-3007843615core:Goodwill2025-04-3007843615core:Goodwill2024-04-3007843615core:FurnitureFittings2025-04-3007843615core:ComputerEquipment2025-04-3007843615core:FurnitureFittings2024-04-3007843615core:ComputerEquipment2024-04-3007843615core:CurrentFinancialInstrumentscore:WithinOneYear2025-04-3007843615core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3007843615core:ShareCapital2025-04-3007843615core:ShareCapital2024-04-3007843615core:RetainedEarningsAccumulatedLosses2025-04-3007843615core:RetainedEarningsAccumulatedLosses2024-04-3007843615bus:Director32024-05-012025-04-3007843615core:Goodwill2024-05-012025-04-3007843615core:FurnitureFittings2024-05-012025-04-3007843615core:ComputerEquipment2024-05-012025-04-3007843615core:Goodwill2024-04-3007843615core:FurnitureFittings2024-04-3007843615core:ComputerEquipment2024-04-30078436152024-04-3007843615core:CurrentFinancialInstruments2025-04-3007843615core:CurrentFinancialInstruments2024-04-3007843615core:WithinOneYear2025-04-3007843615core:WithinOneYear2024-04-3007843615bus:PrivateLimitedCompanyLtd2024-05-012025-04-3007843615bus:SmallCompaniesRegimeForAccounts2024-05-012025-04-3007843615bus:FRS1022024-05-012025-04-3007843615bus:AuditExemptWithAccountantsReport2024-05-012025-04-3007843615bus:Director12024-05-012025-04-3007843615bus:Director22024-05-012025-04-3007843615bus:Director42024-05-012025-04-3007843615bus:FullAccounts2024-05-012025-04-30xbrli:purexbrli:sharesiso4217:GBP